Zebra Capital Management’s BioDelivery Sciences International, Inc. BDSI Stock Holding History

Zebra Capital Management’s Portfolio BDSI Stock Details BDSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-50,887	Closed	-$158K	–	193
2021 Q4	$158K	Sell	50,887 -8,405	-14%	-$28.3K	0.25%	133
2021 Q3	$214K	Buy	59,292 +35,670	+151%	+$135K	0.26%	146
2021 Q2	$85K	Hold	23,622	–	–	0.1%	157
2021 Q1	$92K	Sell	23,622 -120,619	-84%	-$498K	0.1%	165
2020 Q4	$606K	Buy	144,241 +11,799	+9%	+$45.5K	0.77%	47
2020 Q3	$494K	Buy	+132,442	New	+$564K	0.76%	43
2020 Q2	–	Sell	-16,693	Closed	-$63K	–	255
2020 Q1	$63K	Buy	16,693 +3,847	+30%	+$18.9K	0.1%	197
2019 Q4	$81K	Buy	+12,846	New	+$75.5K	0.07%	271

Other funds holding BDSI

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

FCMT

Founders Capital Management (Texas) Houston, Texas $231M AUM 61.68% 1-Year Est. Return

Zebra Capital Management's BDSI Position: Q1 2022 in Review

Zebra Capital Management sold out of BioDelivery Sciences International, Inc. (BDSI) in Q1 2022, closing a stake of 50,887 shares — an estimated $158K sold.

Zebra Capital Management first reported a position in BDSI in Q4 2019 and held it in 8 quarters. The position peaked at $606K in Q4 2020. 2 funds tracked by Wall St. Rank hold BDSI as of Q1 2022.

Zebra Capital Management reported no remaining BioDelivery Sciences International, Inc. position as of Q1 2022 after selling out during the quarter.
Zebra Capital Management sold 50,887 BioDelivery Sciences International, Inc. shares in Q1 2022, an estimated $158K.
Zebra Capital Management first reported a position in BioDelivery Sciences International, Inc. in Q4 2019 and held it in 8 quarters.
Zebra Capital Management's BioDelivery Sciences International, Inc. position peaked at $606K in Q4 2020.
2 funds tracked by Wall St. Rank held BioDelivery Sciences International, Inc. as of Q1 2022.

Based on Zebra Capital Management's 13F filing for Q1 2022, filed 16 May 2022.